Role of inflammation in atrial fibrillation: A comprehensive review of current knowledge.

Abstract

BackgroundAtrial fibrillation (AF) is one of the most common cardiac disorders affecting adults and is associated with significant morbidity and mortality. Efforts to manage AF through anti‐arrhythmics and rate control have been largely unsatisfactory. It has become clear that AF causes structural alterations in the atrial myocardium that propagate further AF, and that some of these alterations are the result of inflammation.MethodsAn in‐depth review of the available literature was undertaken using Google Scholar and keyword searches including [Atrial fibrillation] in combination with [inflammatory markers], [myocardial fibrosis], and [immunomodulators], limiting the search to English language articles. All articles were reviewed for relevance and collated by the author.ResultsMultiple markers of inflammation have been shown to be elevated in AF and to predict responses to treatments of AF including anti‐arrhythmics and cardioversion. The nidus of inflammation is not clear but seems to be related to the pulmonary veins.ConclusionsThe inflammatory cascade induces fibrotic changes in the myocardium, an arrhythmogenic process that stimulates further inflammation. Advances in treatment are focusing on biological agents and immunomodulators that inhibit the inflammatory cascade.